# Marcus O. Butler

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/marcus-o-butler/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,135 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 60 |
| i10-index | 163 |
| Last Known Institution | Princess Margaret Cancer Centre |
| OpenAlex ID | https://openalex.org/A5008158683 |
| ORCID iD | https://orcid.org/0000-0002-9840-7057 |
| Works | 563 |

## Researcher papers

- [Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/overall-survival-benefit-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)
- [Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/three-year-overall-survival-with-tebentafusp-in-metastatic-uveal-melanoma/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Ocular Oncology and Treatments](https://scholariq.org/topics/ocular-oncology-and-treatments/)

## Researcher university

- [Princess Margaret Cancer Centre](https://scholariq.org/institutions/princess-margaret-cancer-centre/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.